Author

Alessandro Armuzzi 1

1 IBD Unit,Complesso Integrato Columbus, Catholic University,R

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Fernando Gomollon Garcia, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James Lindsay, Laurent Peyrin-Biroulet, Garret Cullen, Marco Daperno, Torsten Kucharzik, Florian Rieder, Sven Almer, Alessandro Armuzzi, Marcus Harbord, Jost Langhorst, Miquel Sans, Yehuda Chowers, Gionata Fiorino, Pascal Juillerat, Geras

A MULTINATIONAL STUDY TO DETERMINE INDICATORS OF SUBOPTIMAL THERAPY AMONG ULCERATIVE COLITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR ANTAGONISTS

James Lindsay, Javier Gisbert, Reema Mody, Laurent Peyrin-Biroulet, Alessandro Armuzzi, Bernd Bokemeyer, Geoffrey C. Nguyen, Jean Siebenaler, Örjan Åkerborg, Michael Smyth

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

Amgen - The emerging treatment landscape of IBD: role of innovator biologics and biosimilars (Amgen Europe GmbH)

Alessandro Armuzzi, Jean-Frederic Colombel, Walter Reinisch

Anti-TNF to prevent and treat postoperative recurrence of Crohn's disease

Alessandro Armuzzi

Are we choosing wisely in inflammatory bowel disease care? The IG-IBD choosing wisely campaign

Marco Vincenzo Lenti, Alessandro Armuzzi, Fabiana Castiglione, Massimo Claudio Fantini, Gionata Fiorino, Ambrogio Orlando, Daniela Pugliese, Fernando Rizzello, Maurizio Vecchi, Antonio Di Sabatino

ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS.

Luisa Guidi, Manuela Marzo, Carla Felice, Daniela Pugliese, Gianluca Andrisani, Giammarco Mocci, Olga Maria Nardone, Gian Lodovico Rapaccini, Alfredo Papa, Alessandro Armuzzi, Gian Lodovico Rapaccini

ASSOCIATION BETWEEN DURATION OF LATEST FLARE BEFORE INDUCTION TREATMENT WITH TOFACITINIB AND EFFICACY OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS

Geert D’Haens, Alessandro Armuzzi, Chinyu Su, Xiang Guo, Irene Modesto, Rajiv Mundayat, David P. Hudesman, Michael Chiorean

CANCER AND INFLAMMATORY BOWEL DISEASE PHENOTYPE: A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY

Livia Biancone, Alessandro Armuzzi, Maria Lia Scribano, Renata D'Inca', Claudio Papi, Luisa Spina, Erika Angelucci, Carmelina Petruzziello, Luisa Guidi, Anna Kohn, Filippo Mocciaro, Patrizia Alvisi, Alessandra Ruffa, Rita Monterubbianesi, Walter Fries, Gabriele Riegler, Marco Daperno, Fabiana Castiglione, Giovanna Condino

CHARACTERIZATION OF INCIDENT CASES OF CANCER IN INFLAMMATORY BOWEL DISEASE PATIENTS: RELATION WITH IMMUNOMODULATORY TREATMENTS AND DISEASE PHENOTYPE IN A PROSPECTIVE MULTICENTER MATCHED-PAIR IG-IBD STUDY

Livia Biancone, Giovanna Condino, Alessandro Armuzzi, Maria Scribano, Renata D'Incà, Claudio Papi, Luisa Spina, Luisa Guidi, Anna Kohn, Emma Calabrese, Carmelina Petruzziello, Sara Onali, Filippo Mocciaro, Rita Monterubbianesi, Patrizia Alvisi, Walter Fries, Gabriele Riegler, Irene Frankovic, Giovanna Margagnoni, Gianmic

Item 1 - 10 / 86
1
2 3 4 5 6 7 8 9